doi,publication_date,review_type,review_group,review_mesh_keywords,title,authors,publish_type,is_most_recent_version,url_most_most_version,main_comparison_of_review,main_comparison_population,main_comparison_setting,main_comparison_comparsion_type,background,objectives,search_methods,selection_criteria,data_coll_analysis,main_results,conclusions,summaryTable_count,GRADE_somewhere_in_the_text,is_paywalled,id_measure,Outcomes,relative_effect_95CI,n_participants_studies,GRADE,Comments,effect_statistic,n_participants,n_studies,CI_lower,CI_upper,effect_size,warnings
https://doi.org/10.1002/14651858.CD011897.pub2,20 June 2017,Intervention,Cochrane Airways Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Anti‐Bacterial Agents [therapeutic use];
Bromides [adverse effects, *therapeutic use];
Disease Progression;
Forced Expiratory Volume;
Hospitalization [statistics & numerical data];
Numbers Needed To Treat;
Placebos [therapeutic use];
Pulmonary Disease, Chronic Obstructive [*drug therapy];
Quality of Life;
Quinuclidines [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic;
Smoking [epidemiology];
Steroids [therapeutic use];



Medical Subject Headings Check Words

Female;
Humans;
Male;
Middle Aged;



",Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) ,"Han Ni, Aung Htet, Soe Moe",Review - Intervention,TRUE,NA,Umeclidinium bromide vs placebo for stable chronic obstructive pulmonary disease,people with chronic obstructive pulmonary disease (COPD),community,placebo,"People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long‐acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long‐acting muscarinic antagonists approved for treatment of patients with stable COPD.",To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.,"We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.","We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.  Selection criteria We included randomised controlled trials (RCTs) of parallel design comparing umeclidinium bromide versus placebo in people with COPD, for at least 12 weeks.","We used standard Cochrane methodological procedures. If we noted significant heterogeneity in the meta‐analyses, we subgrouped studies by umeclidinium dose.","We included four studies of 12 to 52 weeks' duration, involving 3798 participants with COPD. Mean age of participants ranged from 60.1 to 64.6 years; most were males with baseline mean smoking pack‐years of 39.2 to 52.3. They had moderate to severe COPD and baseline mean post‐bronchodilator forced expiratory volume in one second (FEV1) ranging from 44.5% to 55.1% of predicted normal. As all studies were systematically conducted according to prespecified protocols, we assessed risk of selection, performance, detection, attrition, and reporting biases as low.  Compared with those given placebo, participants in the umeclidinium group had a lesser likelihood of developing moderate exacerbations requiring a short course of steroids, antibiotics, or both (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.46 to 0.80; four studies, N = 1922; GRADE: high), but not specifically requiring hospitalisations due to severe exacerbations (OR 0.86, 95% CI 0.25 to 2.92; four studies, N = 1922, GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) to prevent an acute exacerbation requiring steroids, antibiotics, or both was 18 (95% CI 13 to 37). Quality of life was better in the umeclidinium group (mean difference (MD) ‐4.79, 95% CI ‐8.84 to ‐0.75; three studies, N = 1119), and these participants had a significantly higher chance of achieving a minimal clinically important difference of at least four units in St George's Respiratory Questionnaire (SGRQ) total score compared with those in the placebo group (OR 1.45, 95% CI 1.16 to 1.82; three studies, N = 1397; GRADE: moderate). The NNTB to achieve one person with a clinically meaningful improvement was 11 (95% CI 7 to 29). The likelihood of all‐cause mortality, non‐fatal serious adverse events (OR 1.33; 95% CI 0.89 to 2.00; four studies, N = 1922, GRADE: moderate), and adverse events (OR 1.06, 95% CI 0.85 to 1.31; four studies, N = 1922; GRADE: moderate) did not differ between umeclidinium and placebo groups. The umeclidinium group demonstrated significantly greater improvement in change from baseline in trough FEV1 compared with the placebo group (MD 0.14, 95% CI 0.12 to 0.17; four studies, N = 1381; GRADE: high). Symptomatic improvement was more likely in the umeclidinium group than in the placebo group, as determined by Transitional Dyspnoea Index (TDI) focal score (MD 0.76, 95% CI 0.43 to 1.09; three studies, N = 1193), and the chance of achieving a minimal clinically important difference of at least one unit improvement was significantly higher with umeclidinium than with placebo (OR 1.71, 95% CI 1.37 to 2.15; three studies, N = 1141; GRADE: high). The NNTB to attain one person with clinically important symptomatic improvement was 8 (95% CI 5 to 14). The likelihood of rescue medication usage (change from baseline in the number of puffs per day) was significantly less for the umeclidinium group than for the placebo group (MD ‐0.45, 95% CI ‐0.76 to ‐0.14; four studies, N = 1531).","Umeclidinium reduced acute exacerbations requiring steroids, antibiotics, or both, although no evidence suggests that it decreased the risk of hospital admission due to exacerbations. Moreover, umeclidinium demonstrated significant improvement in quality of life, lung function, and symptoms, along with lesser use of rescue medications. Studies reported no differences in adverse events, non‐fatal serious adverse events, or mortality between umeclidinium and placebo groups; however, larger studies would yield a more precise estimate for these outcomes.",1,TRUE,FALSE,1,"Number of participants with exacerbations requiring steroids, antibiotics, or both",OR 0.61 (0.46 to 0.80),1922 (4 RCTs),⊕⊕⊕⊕ HIGH,,OR,1922,4,0.46,0.80,OR 0.61,NO warnings
https://doi.org/10.1002/14651858.CD011897.pub2,20 June 2017,Intervention,Cochrane Airways Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Anti‐Bacterial Agents [therapeutic use];
Bromides [adverse effects, *therapeutic use];
Disease Progression;
Forced Expiratory Volume;
Hospitalization [statistics & numerical data];
Numbers Needed To Treat;
Placebos [therapeutic use];
Pulmonary Disease, Chronic Obstructive [*drug therapy];
Quality of Life;
Quinuclidines [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic;
Smoking [epidemiology];
Steroids [therapeutic use];



Medical Subject Headings Check Words

Female;
Humans;
Male;
Middle Aged;



",Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) ,"Han Ni, Aung Htet, Soe Moe",Review - Intervention,TRUE,NA,Umeclidinium bromide vs placebo for stable chronic obstructive pulmonary disease,people with chronic obstructive pulmonary disease (COPD),community,placebo,"People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long‐acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long‐acting muscarinic antagonists approved for treatment of patients with stable COPD.",To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.,"We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.","We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.  Selection criteria We included randomised controlled trials (RCTs) of parallel design comparing umeclidinium bromide versus placebo in people with COPD, for at least 12 weeks.","We used standard Cochrane methodological procedures. If we noted significant heterogeneity in the meta‐analyses, we subgrouped studies by umeclidinium dose.","We included four studies of 12 to 52 weeks' duration, involving 3798 participants with COPD. Mean age of participants ranged from 60.1 to 64.6 years; most were males with baseline mean smoking pack‐years of 39.2 to 52.3. They had moderate to severe COPD and baseline mean post‐bronchodilator forced expiratory volume in one second (FEV1) ranging from 44.5% to 55.1% of predicted normal. As all studies were systematically conducted according to prespecified protocols, we assessed risk of selection, performance, detection, attrition, and reporting biases as low.  Compared with those given placebo, participants in the umeclidinium group had a lesser likelihood of developing moderate exacerbations requiring a short course of steroids, antibiotics, or both (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.46 to 0.80; four studies, N = 1922; GRADE: high), but not specifically requiring hospitalisations due to severe exacerbations (OR 0.86, 95% CI 0.25 to 2.92; four studies, N = 1922, GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) to prevent an acute exacerbation requiring steroids, antibiotics, or both was 18 (95% CI 13 to 37). Quality of life was better in the umeclidinium group (mean difference (MD) ‐4.79, 95% CI ‐8.84 to ‐0.75; three studies, N = 1119), and these participants had a significantly higher chance of achieving a minimal clinically important difference of at least four units in St George's Respiratory Questionnaire (SGRQ) total score compared with those in the placebo group (OR 1.45, 95% CI 1.16 to 1.82; three studies, N = 1397; GRADE: moderate). The NNTB to achieve one person with a clinically meaningful improvement was 11 (95% CI 7 to 29). The likelihood of all‐cause mortality, non‐fatal serious adverse events (OR 1.33; 95% CI 0.89 to 2.00; four studies, N = 1922, GRADE: moderate), and adverse events (OR 1.06, 95% CI 0.85 to 1.31; four studies, N = 1922; GRADE: moderate) did not differ between umeclidinium and placebo groups. The umeclidinium group demonstrated significantly greater improvement in change from baseline in trough FEV1 compared with the placebo group (MD 0.14, 95% CI 0.12 to 0.17; four studies, N = 1381; GRADE: high). Symptomatic improvement was more likely in the umeclidinium group than in the placebo group, as determined by Transitional Dyspnoea Index (TDI) focal score (MD 0.76, 95% CI 0.43 to 1.09; three studies, N = 1193), and the chance of achieving a minimal clinically important difference of at least one unit improvement was significantly higher with umeclidinium than with placebo (OR 1.71, 95% CI 1.37 to 2.15; three studies, N = 1141; GRADE: high). The NNTB to attain one person with clinically important symptomatic improvement was 8 (95% CI 5 to 14). The likelihood of rescue medication usage (change from baseline in the number of puffs per day) was significantly less for the umeclidinium group than for the placebo group (MD ‐0.45, 95% CI ‐0.76 to ‐0.14; four studies, N = 1531).","Umeclidinium reduced acute exacerbations requiring steroids, antibiotics, or both, although no evidence suggests that it decreased the risk of hospital admission due to exacerbations. Moreover, umeclidinium demonstrated significant improvement in quality of life, lung function, and symptoms, along with lesser use of rescue medications. Studies reported no differences in adverse events, non‐fatal serious adverse events, or mortality between umeclidinium and placebo groups; however, larger studies would yield a more precise estimate for these outcomes.",1,TRUE,FALSE,2,Quality of life: number of participants with ≥ 4 units improvement in SGRQ total score,OR 1.45 (1.16 to 1.82),1397 (3 RCTs),⊕⊕⊕⊝ MODERATEa,"Mean quality of life: change from baseline in SGRQ total score was 4.79 lower (8.84 lower to 0.75 lower) in umeclidinium group (1119 participants, 3 RCTs)",OR Mean quality of life: change from baseline in SGRQ total score,1397,3,1.16,1.82,OR 1.45,NO warnings
https://doi.org/10.1002/14651858.CD011897.pub2,20 June 2017,Intervention,Cochrane Airways Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Anti‐Bacterial Agents [therapeutic use];
Bromides [adverse effects, *therapeutic use];
Disease Progression;
Forced Expiratory Volume;
Hospitalization [statistics & numerical data];
Numbers Needed To Treat;
Placebos [therapeutic use];
Pulmonary Disease, Chronic Obstructive [*drug therapy];
Quality of Life;
Quinuclidines [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic;
Smoking [epidemiology];
Steroids [therapeutic use];



Medical Subject Headings Check Words

Female;
Humans;
Male;
Middle Aged;



",Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) ,"Han Ni, Aung Htet, Soe Moe",Review - Intervention,TRUE,NA,Umeclidinium bromide vs placebo for stable chronic obstructive pulmonary disease,people with chronic obstructive pulmonary disease (COPD),community,placebo,"People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long‐acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long‐acting muscarinic antagonists approved for treatment of patients with stable COPD.",To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.,"We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.","We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.  Selection criteria We included randomised controlled trials (RCTs) of parallel design comparing umeclidinium bromide versus placebo in people with COPD, for at least 12 weeks.","We used standard Cochrane methodological procedures. If we noted significant heterogeneity in the meta‐analyses, we subgrouped studies by umeclidinium dose.","We included four studies of 12 to 52 weeks' duration, involving 3798 participants with COPD. Mean age of participants ranged from 60.1 to 64.6 years; most were males with baseline mean smoking pack‐years of 39.2 to 52.3. They had moderate to severe COPD and baseline mean post‐bronchodilator forced expiratory volume in one second (FEV1) ranging from 44.5% to 55.1% of predicted normal. As all studies were systematically conducted according to prespecified protocols, we assessed risk of selection, performance, detection, attrition, and reporting biases as low.  Compared with those given placebo, participants in the umeclidinium group had a lesser likelihood of developing moderate exacerbations requiring a short course of steroids, antibiotics, or both (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.46 to 0.80; four studies, N = 1922; GRADE: high), but not specifically requiring hospitalisations due to severe exacerbations (OR 0.86, 95% CI 0.25 to 2.92; four studies, N = 1922, GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) to prevent an acute exacerbation requiring steroids, antibiotics, or both was 18 (95% CI 13 to 37). Quality of life was better in the umeclidinium group (mean difference (MD) ‐4.79, 95% CI ‐8.84 to ‐0.75; three studies, N = 1119), and these participants had a significantly higher chance of achieving a minimal clinically important difference of at least four units in St George's Respiratory Questionnaire (SGRQ) total score compared with those in the placebo group (OR 1.45, 95% CI 1.16 to 1.82; three studies, N = 1397; GRADE: moderate). The NNTB to achieve one person with a clinically meaningful improvement was 11 (95% CI 7 to 29). The likelihood of all‐cause mortality, non‐fatal serious adverse events (OR 1.33; 95% CI 0.89 to 2.00; four studies, N = 1922, GRADE: moderate), and adverse events (OR 1.06, 95% CI 0.85 to 1.31; four studies, N = 1922; GRADE: moderate) did not differ between umeclidinium and placebo groups. The umeclidinium group demonstrated significantly greater improvement in change from baseline in trough FEV1 compared with the placebo group (MD 0.14, 95% CI 0.12 to 0.17; four studies, N = 1381; GRADE: high). Symptomatic improvement was more likely in the umeclidinium group than in the placebo group, as determined by Transitional Dyspnoea Index (TDI) focal score (MD 0.76, 95% CI 0.43 to 1.09; three studies, N = 1193), and the chance of achieving a minimal clinically important difference of at least one unit improvement was significantly higher with umeclidinium than with placebo (OR 1.71, 95% CI 1.37 to 2.15; three studies, N = 1141; GRADE: high). The NNTB to attain one person with clinically important symptomatic improvement was 8 (95% CI 5 to 14). The likelihood of rescue medication usage (change from baseline in the number of puffs per day) was significantly less for the umeclidinium group than for the placebo group (MD ‐0.45, 95% CI ‐0.76 to ‐0.14; four studies, N = 1531).","Umeclidinium reduced acute exacerbations requiring steroids, antibiotics, or both, although no evidence suggests that it decreased the risk of hospital admission due to exacerbations. Moreover, umeclidinium demonstrated significant improvement in quality of life, lung function, and symptoms, along with lesser use of rescue medications. Studies reported no differences in adverse events, non‐fatal serious adverse events, or mortality between umeclidinium and placebo groups; however, larger studies would yield a more precise estimate for these outcomes.",1,TRUE,FALSE,3,Non‐fatal serious adverse events,OR 1.33 (0.89 to 2.00),1922 (4 RCTs),⊕⊕⊕⊝ MODERATEb,Larger studies may help refine this estimate,OR,1922,4,0.89,2.00,OR 1.33,NO warnings
https://doi.org/10.1002/14651858.CD011897.pub2,20 June 2017,Intervention,Cochrane Airways Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Anti‐Bacterial Agents [therapeutic use];
Bromides [adverse effects, *therapeutic use];
Disease Progression;
Forced Expiratory Volume;
Hospitalization [statistics & numerical data];
Numbers Needed To Treat;
Placebos [therapeutic use];
Pulmonary Disease, Chronic Obstructive [*drug therapy];
Quality of Life;
Quinuclidines [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic;
Smoking [epidemiology];
Steroids [therapeutic use];



Medical Subject Headings Check Words

Female;
Humans;
Male;
Middle Aged;



",Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) ,"Han Ni, Aung Htet, Soe Moe",Review - Intervention,TRUE,NA,Umeclidinium bromide vs placebo for stable chronic obstructive pulmonary disease,people with chronic obstructive pulmonary disease (COPD),community,placebo,"People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long‐acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long‐acting muscarinic antagonists approved for treatment of patients with stable COPD.",To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.,"We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.","We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.  Selection criteria We included randomised controlled trials (RCTs) of parallel design comparing umeclidinium bromide versus placebo in people with COPD, for at least 12 weeks.","We used standard Cochrane methodological procedures. If we noted significant heterogeneity in the meta‐analyses, we subgrouped studies by umeclidinium dose.","We included four studies of 12 to 52 weeks' duration, involving 3798 participants with COPD. Mean age of participants ranged from 60.1 to 64.6 years; most were males with baseline mean smoking pack‐years of 39.2 to 52.3. They had moderate to severe COPD and baseline mean post‐bronchodilator forced expiratory volume in one second (FEV1) ranging from 44.5% to 55.1% of predicted normal. As all studies were systematically conducted according to prespecified protocols, we assessed risk of selection, performance, detection, attrition, and reporting biases as low.  Compared with those given placebo, participants in the umeclidinium group had a lesser likelihood of developing moderate exacerbations requiring a short course of steroids, antibiotics, or both (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.46 to 0.80; four studies, N = 1922; GRADE: high), but not specifically requiring hospitalisations due to severe exacerbations (OR 0.86, 95% CI 0.25 to 2.92; four studies, N = 1922, GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) to prevent an acute exacerbation requiring steroids, antibiotics, or both was 18 (95% CI 13 to 37). Quality of life was better in the umeclidinium group (mean difference (MD) ‐4.79, 95% CI ‐8.84 to ‐0.75; three studies, N = 1119), and these participants had a significantly higher chance of achieving a minimal clinically important difference of at least four units in St George's Respiratory Questionnaire (SGRQ) total score compared with those in the placebo group (OR 1.45, 95% CI 1.16 to 1.82; three studies, N = 1397; GRADE: moderate). The NNTB to achieve one person with a clinically meaningful improvement was 11 (95% CI 7 to 29). The likelihood of all‐cause mortality, non‐fatal serious adverse events (OR 1.33; 95% CI 0.89 to 2.00; four studies, N = 1922, GRADE: moderate), and adverse events (OR 1.06, 95% CI 0.85 to 1.31; four studies, N = 1922; GRADE: moderate) did not differ between umeclidinium and placebo groups. The umeclidinium group demonstrated significantly greater improvement in change from baseline in trough FEV1 compared with the placebo group (MD 0.14, 95% CI 0.12 to 0.17; four studies, N = 1381; GRADE: high). Symptomatic improvement was more likely in the umeclidinium group than in the placebo group, as determined by Transitional Dyspnoea Index (TDI) focal score (MD 0.76, 95% CI 0.43 to 1.09; three studies, N = 1193), and the chance of achieving a minimal clinically important difference of at least one unit improvement was significantly higher with umeclidinium than with placebo (OR 1.71, 95% CI 1.37 to 2.15; three studies, N = 1141; GRADE: high). The NNTB to attain one person with clinically important symptomatic improvement was 8 (95% CI 5 to 14). The likelihood of rescue medication usage (change from baseline in the number of puffs per day) was significantly less for the umeclidinium group than for the placebo group (MD ‐0.45, 95% CI ‐0.76 to ‐0.14; four studies, N = 1531).","Umeclidinium reduced acute exacerbations requiring steroids, antibiotics, or both, although no evidence suggests that it decreased the risk of hospital admission due to exacerbations. Moreover, umeclidinium demonstrated significant improvement in quality of life, lung function, and symptoms, along with lesser use of rescue medications. Studies reported no differences in adverse events, non‐fatal serious adverse events, or mortality between umeclidinium and placebo groups; however, larger studies would yield a more precise estimate for these outcomes.",1,TRUE,FALSE,4,Number of participants with hospital admissions due to COPD exacerbation,OR 0.86 (0.25 to 2.92),1922 (4 RCTs),⊕⊕⊝⊝ LOWc,"Few events, so larger studies may help refine this estimate",OR,1922,4,0.25,2.92,OR 0.86,NO warnings
https://doi.org/10.1002/14651858.CD011897.pub2,20 June 2017,Intervention,Cochrane Airways Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Anti‐Bacterial Agents [therapeutic use];
Bromides [adverse effects, *therapeutic use];
Disease Progression;
Forced Expiratory Volume;
Hospitalization [statistics & numerical data];
Numbers Needed To Treat;
Placebos [therapeutic use];
Pulmonary Disease, Chronic Obstructive [*drug therapy];
Quality of Life;
Quinuclidines [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic;
Smoking [epidemiology];
Steroids [therapeutic use];



Medical Subject Headings Check Words

Female;
Humans;
Male;
Middle Aged;



",Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) ,"Han Ni, Aung Htet, Soe Moe",Review - Intervention,TRUE,NA,Umeclidinium bromide vs placebo for stable chronic obstructive pulmonary disease,people with chronic obstructive pulmonary disease (COPD),community,placebo,"People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long‐acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long‐acting muscarinic antagonists approved for treatment of patients with stable COPD.",To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.,"We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.","We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.  Selection criteria We included randomised controlled trials (RCTs) of parallel design comparing umeclidinium bromide versus placebo in people with COPD, for at least 12 weeks.","We used standard Cochrane methodological procedures. If we noted significant heterogeneity in the meta‐analyses, we subgrouped studies by umeclidinium dose.","We included four studies of 12 to 52 weeks' duration, involving 3798 participants with COPD. Mean age of participants ranged from 60.1 to 64.6 years; most were males with baseline mean smoking pack‐years of 39.2 to 52.3. They had moderate to severe COPD and baseline mean post‐bronchodilator forced expiratory volume in one second (FEV1) ranging from 44.5% to 55.1% of predicted normal. As all studies were systematically conducted according to prespecified protocols, we assessed risk of selection, performance, detection, attrition, and reporting biases as low.  Compared with those given placebo, participants in the umeclidinium group had a lesser likelihood of developing moderate exacerbations requiring a short course of steroids, antibiotics, or both (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.46 to 0.80; four studies, N = 1922; GRADE: high), but not specifically requiring hospitalisations due to severe exacerbations (OR 0.86, 95% CI 0.25 to 2.92; four studies, N = 1922, GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) to prevent an acute exacerbation requiring steroids, antibiotics, or both was 18 (95% CI 13 to 37). Quality of life was better in the umeclidinium group (mean difference (MD) ‐4.79, 95% CI ‐8.84 to ‐0.75; three studies, N = 1119), and these participants had a significantly higher chance of achieving a minimal clinically important difference of at least four units in St George's Respiratory Questionnaire (SGRQ) total score compared with those in the placebo group (OR 1.45, 95% CI 1.16 to 1.82; three studies, N = 1397; GRADE: moderate). The NNTB to achieve one person with a clinically meaningful improvement was 11 (95% CI 7 to 29). The likelihood of all‐cause mortality, non‐fatal serious adverse events (OR 1.33; 95% CI 0.89 to 2.00; four studies, N = 1922, GRADE: moderate), and adverse events (OR 1.06, 95% CI 0.85 to 1.31; four studies, N = 1922; GRADE: moderate) did not differ between umeclidinium and placebo groups. The umeclidinium group demonstrated significantly greater improvement in change from baseline in trough FEV1 compared with the placebo group (MD 0.14, 95% CI 0.12 to 0.17; four studies, N = 1381; GRADE: high). Symptomatic improvement was more likely in the umeclidinium group than in the placebo group, as determined by Transitional Dyspnoea Index (TDI) focal score (MD 0.76, 95% CI 0.43 to 1.09; three studies, N = 1193), and the chance of achieving a minimal clinically important difference of at least one unit improvement was significantly higher with umeclidinium than with placebo (OR 1.71, 95% CI 1.37 to 2.15; three studies, N = 1141; GRADE: high). The NNTB to attain one person with clinically important symptomatic improvement was 8 (95% CI 5 to 14). The likelihood of rescue medication usage (change from baseline in the number of puffs per day) was significantly less for the umeclidinium group than for the placebo group (MD ‐0.45, 95% CI ‐0.76 to ‐0.14; four studies, N = 1531).","Umeclidinium reduced acute exacerbations requiring steroids, antibiotics, or both, although no evidence suggests that it decreased the risk of hospital admission due to exacerbations. Moreover, umeclidinium demonstrated significant improvement in quality of life, lung function, and symptoms, along with lesser use of rescue medications. Studies reported no differences in adverse events, non‐fatal serious adverse events, or mortality between umeclidinium and placebo groups; however, larger studies would yield a more precise estimate for these outcomes.",1,TRUE,FALSE,5,Number of participants with ≥ 1 unit improvement in TDI focal score,OR 1.71 (1.37 to 2.15),1441 (3 RCTs),⊕⊕⊕⊕ HIGH,"Mean improvement in TDI focal score change from baseline was 0.76 higher (0.43 higher to 1.09 higher) in umeclidinium group (1193 participants, 3 RCTs)",OR Mean improvement in TDI focal score,1441,3,1.37,2.15,OR 1.71,NO warnings
https://doi.org/10.1002/14651858.CD011897.pub2,20 June 2017,Intervention,Cochrane Airways Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Anti‐Bacterial Agents [therapeutic use];
Bromides [adverse effects, *therapeutic use];
Disease Progression;
Forced Expiratory Volume;
Hospitalization [statistics & numerical data];
Numbers Needed To Treat;
Placebos [therapeutic use];
Pulmonary Disease, Chronic Obstructive [*drug therapy];
Quality of Life;
Quinuclidines [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic;
Smoking [epidemiology];
Steroids [therapeutic use];



Medical Subject Headings Check Words

Female;
Humans;
Male;
Middle Aged;



",Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) ,"Han Ni, Aung Htet, Soe Moe",Review - Intervention,TRUE,NA,Umeclidinium bromide vs placebo for stable chronic obstructive pulmonary disease,people with chronic obstructive pulmonary disease (COPD),community,placebo,"People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long‐acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long‐acting muscarinic antagonists approved for treatment of patients with stable COPD.",To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.,"We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.","We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.  Selection criteria We included randomised controlled trials (RCTs) of parallel design comparing umeclidinium bromide versus placebo in people with COPD, for at least 12 weeks.","We used standard Cochrane methodological procedures. If we noted significant heterogeneity in the meta‐analyses, we subgrouped studies by umeclidinium dose.","We included four studies of 12 to 52 weeks' duration, involving 3798 participants with COPD. Mean age of participants ranged from 60.1 to 64.6 years; most were males with baseline mean smoking pack‐years of 39.2 to 52.3. They had moderate to severe COPD and baseline mean post‐bronchodilator forced expiratory volume in one second (FEV1) ranging from 44.5% to 55.1% of predicted normal. As all studies were systematically conducted according to prespecified protocols, we assessed risk of selection, performance, detection, attrition, and reporting biases as low.  Compared with those given placebo, participants in the umeclidinium group had a lesser likelihood of developing moderate exacerbations requiring a short course of steroids, antibiotics, or both (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.46 to 0.80; four studies, N = 1922; GRADE: high), but not specifically requiring hospitalisations due to severe exacerbations (OR 0.86, 95% CI 0.25 to 2.92; four studies, N = 1922, GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) to prevent an acute exacerbation requiring steroids, antibiotics, or both was 18 (95% CI 13 to 37). Quality of life was better in the umeclidinium group (mean difference (MD) ‐4.79, 95% CI ‐8.84 to ‐0.75; three studies, N = 1119), and these participants had a significantly higher chance of achieving a minimal clinically important difference of at least four units in St George's Respiratory Questionnaire (SGRQ) total score compared with those in the placebo group (OR 1.45, 95% CI 1.16 to 1.82; three studies, N = 1397; GRADE: moderate). The NNTB to achieve one person with a clinically meaningful improvement was 11 (95% CI 7 to 29). The likelihood of all‐cause mortality, non‐fatal serious adverse events (OR 1.33; 95% CI 0.89 to 2.00; four studies, N = 1922, GRADE: moderate), and adverse events (OR 1.06, 95% CI 0.85 to 1.31; four studies, N = 1922; GRADE: moderate) did not differ between umeclidinium and placebo groups. The umeclidinium group demonstrated significantly greater improvement in change from baseline in trough FEV1 compared with the placebo group (MD 0.14, 95% CI 0.12 to 0.17; four studies, N = 1381; GRADE: high). Symptomatic improvement was more likely in the umeclidinium group than in the placebo group, as determined by Transitional Dyspnoea Index (TDI) focal score (MD 0.76, 95% CI 0.43 to 1.09; three studies, N = 1193), and the chance of achieving a minimal clinically important difference of at least one unit improvement was significantly higher with umeclidinium than with placebo (OR 1.71, 95% CI 1.37 to 2.15; three studies, N = 1141; GRADE: high). The NNTB to attain one person with clinically important symptomatic improvement was 8 (95% CI 5 to 14). The likelihood of rescue medication usage (change from baseline in the number of puffs per day) was significantly less for the umeclidinium group than for the placebo group (MD ‐0.45, 95% CI ‐0.76 to ‐0.14; four studies, N = 1531).","Umeclidinium reduced acute exacerbations requiring steroids, antibiotics, or both, although no evidence suggests that it decreased the risk of hospital admission due to exacerbations. Moreover, umeclidinium demonstrated significant improvement in quality of life, lung function, and symptoms, along with lesser use of rescue medications. Studies reported no differences in adverse events, non‐fatal serious adverse events, or mortality between umeclidinium and placebo groups; however, larger studies would yield a more precise estimate for these outcomes.",1,TRUE,FALSE,6,Change from baseline in trough FEV1 (L),‐,1381 (4 RCTs),⊕⊕⊕⊕ HIGH,,"NA",1381,4,NA,NA,NA,NO warnings
https://doi.org/10.1002/14651858.CD011897.pub2,20 June 2017,Intervention,Cochrane Airways Group,"Keywords


Medical Subject Headings (MeSH) Keywords

Anti‐Bacterial Agents [therapeutic use];
Bromides [adverse effects, *therapeutic use];
Disease Progression;
Forced Expiratory Volume;
Hospitalization [statistics & numerical data];
Numbers Needed To Treat;
Placebos [therapeutic use];
Pulmonary Disease, Chronic Obstructive [*drug therapy];
Quality of Life;
Quinuclidines [adverse effects, *therapeutic use];
Randomized Controlled Trials as Topic;
Smoking [epidemiology];
Steroids [therapeutic use];



Medical Subject Headings Check Words

Female;
Humans;
Male;
Middle Aged;



",Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) ,"Han Ni, Aung Htet, Soe Moe",Review - Intervention,TRUE,NA,Umeclidinium bromide vs placebo for stable chronic obstructive pulmonary disease,people with chronic obstructive pulmonary disease (COPD),community,placebo,"People with chronic obstructive pulmonary disease (COPD) have poor quality of life, reduced survival, and accelerated decline in lung function, especially associated with acute exacerbations, leading to high healthcare costs. Long‐acting bronchodilators are the mainstay of treatment for symptomatic improvement, and umeclidinium is one of the new long‐acting muscarinic antagonists approved for treatment of patients with stable COPD.",To assess the efficacy and safety of umeclidinium bromide versus placebo for people with stable COPD.,"We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.","We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, the World Health Organization (WHO) trials portal, and the GlaxoSmithKline (GSK) Clinical Study Register, using prespecified terms, as well as the reference lists of all identified studies. Searches are current to April 2017.  Selection criteria We included randomised controlled trials (RCTs) of parallel design comparing umeclidinium bromide versus placebo in people with COPD, for at least 12 weeks.","We used standard Cochrane methodological procedures. If we noted significant heterogeneity in the meta‐analyses, we subgrouped studies by umeclidinium dose.","We included four studies of 12 to 52 weeks' duration, involving 3798 participants with COPD. Mean age of participants ranged from 60.1 to 64.6 years; most were males with baseline mean smoking pack‐years of 39.2 to 52.3. They had moderate to severe COPD and baseline mean post‐bronchodilator forced expiratory volume in one second (FEV1) ranging from 44.5% to 55.1% of predicted normal. As all studies were systematically conducted according to prespecified protocols, we assessed risk of selection, performance, detection, attrition, and reporting biases as low.  Compared with those given placebo, participants in the umeclidinium group had a lesser likelihood of developing moderate exacerbations requiring a short course of steroids, antibiotics, or both (odds ratio (OR) 0.61, 95% confidence interval (CI) 0.46 to 0.80; four studies, N = 1922; GRADE: high), but not specifically requiring hospitalisations due to severe exacerbations (OR 0.86, 95% CI 0.25 to 2.92; four studies, N = 1922, GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) to prevent an acute exacerbation requiring steroids, antibiotics, or both was 18 (95% CI 13 to 37). Quality of life was better in the umeclidinium group (mean difference (MD) ‐4.79, 95% CI ‐8.84 to ‐0.75; three studies, N = 1119), and these participants had a significantly higher chance of achieving a minimal clinically important difference of at least four units in St George's Respiratory Questionnaire (SGRQ) total score compared with those in the placebo group (OR 1.45, 95% CI 1.16 to 1.82; three studies, N = 1397; GRADE: moderate). The NNTB to achieve one person with a clinically meaningful improvement was 11 (95% CI 7 to 29). The likelihood of all‐cause mortality, non‐fatal serious adverse events (OR 1.33; 95% CI 0.89 to 2.00; four studies, N = 1922, GRADE: moderate), and adverse events (OR 1.06, 95% CI 0.85 to 1.31; four studies, N = 1922; GRADE: moderate) did not differ between umeclidinium and placebo groups. The umeclidinium group demonstrated significantly greater improvement in change from baseline in trough FEV1 compared with the placebo group (MD 0.14, 95% CI 0.12 to 0.17; four studies, N = 1381; GRADE: high). Symptomatic improvement was more likely in the umeclidinium group than in the placebo group, as determined by Transitional Dyspnoea Index (TDI) focal score (MD 0.76, 95% CI 0.43 to 1.09; three studies, N = 1193), and the chance of achieving a minimal clinically important difference of at least one unit improvement was significantly higher with umeclidinium than with placebo (OR 1.71, 95% CI 1.37 to 2.15; three studies, N = 1141; GRADE: high). The NNTB to attain one person with clinically important symptomatic improvement was 8 (95% CI 5 to 14). The likelihood of rescue medication usage (change from baseline in the number of puffs per day) was significantly less for the umeclidinium group than for the placebo group (MD ‐0.45, 95% CI ‐0.76 to ‐0.14; four studies, N = 1531).","Umeclidinium reduced acute exacerbations requiring steroids, antibiotics, or both, although no evidence suggests that it decreased the risk of hospital admission due to exacerbations. Moreover, umeclidinium demonstrated significant improvement in quality of life, lung function, and symptoms, along with lesser use of rescue medications. Studies reported no differences in adverse events, non‐fatal serious adverse events, or mortality between umeclidinium and placebo groups; however, larger studies would yield a more precise estimate for these outcomes.",1,TRUE,FALSE,7,Adverse events (not including serious adverse events),OR 1.06 (0.85 to 1.31),1922 (4 RCTs),⊕⊕⊕⊝ MODERATEb,,OR,1922,4,0.85,1.31,OR 1.06,NO warnings
